Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company headquartered in Shanghai and New York, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to BW-20805, an investigational small interfering RNA (siRNA) therapy targeting prekallikrein (PKK) mRNA, for the treatment of hereditary angioedema (HAE). BW-20805 inhibits hepatic PKK gene expression, aiming to reduce plasma PKK levels and prevent HAE attacks. The drug also holds FDA Orphan Drug Designation for the same indication.
Fast Track Designation enables early and frequent communication with the FDA throughout development and review. It permits rolling submission of a New Drug Application (NDA), meaning completed sections can be reviewed on an ongoing basis rather than as a single package. Products carrying the designation may also qualify for Priority Review at the time of NDA filing, contingent on meeting relevant criteria.
Argo Biopharma is conducting a global Phase II open-label study of BW-20805 in adult HAE patients (NCT06846398). The company expects primary completion in the second half of 2026, with plans for a global Phase III study to follow. Earlier in development, BW-20805 completed Phase I trials in healthy subjects evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics. The company has stated that open-label results presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting showed plasma PKK reduction and a reduction in time-normalized HAE attack rates, though specific numerical endpoints and p-values were not disclosed in the press release. Argo Biopharma maintains a pipeline of seven RNA interference (RNAi) candidates across cardiovascular, viral, metabolic, and rare disease indications. The "BW" prefix in the drug code indicates the molecule originated with Suzhou Biowise Biopharmaceutical Co., Ltd., a China-based company, and was licensed by Argo Biopharma for global development.
Research context
HAE is a rare genetic disorder affecting approximately 1.5 per 100,000 people worldwide, characterized by unpredictable episodes of subcutaneous or submucosal swelling. Laryngeal attacks carry a mortality rate reported at up to 40% without treatment. Current prophylactic options include lanadelumab (Takhzyro, Takeda), a monoclonal antibody targeting plasma kallikrein administered subcutaneously every two to four weeks, and berotralstat (Orladeyo, BioCryst Pharmaceuticals), an oral plasma kallikrein inhibitor dosed daily. CSL Behring's garadacimab, a monoclonal antibody targeting activated Factor XII (FXIIa), has received regulatory submissions in multiple regions. No siRNA therapy has yet been approved for HAE.
BW-20805 differs from these marketed and late-stage agents in both modality and mechanism. Where lanadelumab and berotralstat act at the protein level — binding kallikrein or inhibiting its enzymatic activity — BW-20805 operates upstream by degrading PKK mRNA through RNA interference, preventing the protein from being synthesized. This approach parallels the mechanism used by Alnylam Pharmaceuticals' marketed siRNA therapies in other indications, though BW-20805 targets a distinct gene. The siRNA modality may allow for less frequent dosing than existing prophylactic treatments, though the dosing interval for BW-20805 has not been publicly confirmed with Phase II data. Garadacimab targets a different node in the contact activation pathway — FXIIa rather than PKK — and is also administered subcutaneously.
The HAE prophylaxis market remains active. Despite multiple approved therapies, the press release notes that current options are limited by dosing frequency, a claim consistent with the biweekly-to-monthly injection schedule of lanadelumab and the daily oral dosing of berotralstat. Whether BW-20805 can demonstrate a clinically differentiated dosing profile will depend on Phase II and Phase III data. The absence of disclosed efficacy metrics from the ongoing Phase II trial leaves open questions about the magnitude of attack rate reduction relative to existing therapies. The company's timeline places Phase III initiation after the second half of 2026, suggesting a regulatory filing would not occur before 2028 at the earliest, assuming standard development timelines.
Spot something wrong? Report an issue with this article